Oura's 4x Oversubscribed IPO Validates Smart Ring Category: Eli Lilly, Dragoneer Back $2.2B Offering

Wall Street is all in on smart rings. Oura's IPO — pricing today on the Nasdaq — has drawn roughly four times as many orders as shares available, according to people familiar with the matter. Cornerstone investors Eli Lilly and Dragoneer Investment Group have indicated interest in $400 million of the $2.2 billion offering, accounting for roughly 19% of the deal.

What the Oversubscription Signals

• Category validation: Smart rings are no longer a niche — institutional investors see a health platform, not a gadget
• Pharma integration: Eli Lilly's $100M commitment ties to its GLP-1 drug monitoring partnership with Oura
• Growth trajectory: Subscription revenue grew 121% YoY to $240.5 million, with 85% 12-month member retention

Impact on Competitors

A $15.6 billion public Oura raises the bar for every smart ring maker. Samsung's Galaxy Ring 2 remains delayed by patent issues, while RingConn and Ultrahuman compete on no-subscription models. Oura's IPO war chest gives it resources to defend its 75% market share through R&D and marketing.

Should You Buy an Oura Ring Now?

The IPO doesn't change the product, but post-IPO promotional pricing is likely as Oura targets subscriber growth. The Oura Ring 5 launched at $399 and remains the category leader. Browse all options in our smart ring comparison.